Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims



    Explore by Goal












     Quick Explanation


    Molly A. Bogue (M. Bogue): strengths lie in building and validating mouse genetics/phenome resources and in immunogenetics/genetics—evidenced by widely cited foundational work on the Collaborative Cross and phenotyping infrastructure.
    Key evidence:
    • Collaborative Cross resource:
    • MIBBI reporting guidelines:
    • Mouse Phenome Database (MPD):



     Long Explanation


    Author Review (Science-focused): Molly A. Bogue
    Skeptical, evidence-based critique of scientific impact and rigor based on the author’s identifiable publication record provided in the prompt.

    1) Research-output tempo (from provided OpenAlex yearly counts)

    2) Citation-attraction over time (from provided yearly cited_by counts)

    3) Evidence-weighted strengths (with primary-source grounding)

    A. Foundational mouse-genetics resources + community impact
    Bogue’s record prominently includes creation/curation of mouse genetic resources and phenotype infrastructure, which tend to yield long-lived scientific utility because they standardize genotypes, mapping power, and phenotype access.
    • Collaborative Cross: a community genetic resource for mapping complex traits; high citation durability is consistent with enabling reproducible cross-study genetics.
    • Mouse Phenome Database (MPD): integration of curated phenotypes into an analysis/query framework, which supports cross-lab reuse of phenotype evidence.
    B. Reproducibility & reporting standards focus
    A second strength is explicit methodological stewardship: reporting guidelines and data/metadata adequacy.
    • MIBBI minimum reporting guidelines: targets missing methodological details that otherwise prevent faithful replication or meta-analysis.
    C. Immunogenetics / mechanistic mouse biology foundations
    Early work includes immunobiology with mechanistic relevance (V(D)J recombination and immune deficiency models), supporting cross-cutting expertise beyond database/resource building.
    • Ku86-deficient mice: severe combined immunodeficiency with defective processing of V(D)J recombination intermediates.

    4) Evidence map (what types of contributions these papers represent)

    Supporting variant-map example included in the provided OpenAlex list:

    5) Scientific skepticism: what we can & cannot infer

    Known from the evidence provided
    • There is clear documentation (via DOIs for several items) of involvement in major mouse genetics/phenome resource building ().
    • There is direct support for reproducibility/metadata reporting emphasis via MIBBI ().
    • There is mechanistic immunogenetics evidence via Ku86 deficiency affecting V(D)J recombination intermediates ().
    Uncertainty / possible blindspots
    • Selection bias in shown evidence: only a small subset of the author’s listed works has explicit DOIs in the prompt; therefore, claims about “overall” topic breadth beyond these cited examples remain uncertain.
    • Correlation vs causation in citation strength: high citation counts can reflect utility, but they also can reflect community adoption and network effects—not necessarily that every included study is methodologically flawless.
    • Reproducibility limitations: even with resources/guidelines, reproducibility can still fail due to lab-to-lab procedural variation, phenotype definition drift, and statistical-modeling choices. Reporting guidelines help, but do not guarantee replication.
    • Cross-species generalization caution: mouse genetic mechanisms often illuminate biology, but mapping/phenotype findings do not automatically translate to human biology because of species differences in immune development, metabolism, and environmental exposures.

    6) Practical takeaway for users (how to leverage this author’s strengths)

    • If you need mouse genotype→phenotype evidence integration, the MPD ecosystem and Collaborative Cross framing are directly relevant ().
    • If you are writing methods/metadata or curating evidence for meta-analysis, MIBBI-style checklists can improve comparability ().
    • If you study immune-receptor machinery, early mechanistic mouse immune phenotypes (e.g., V(D)J recombination defects) offer mechanistic anchors ().


    Feedback:    

    Updated: April 29, 2026

     BGPT Author Review


    Scientific Quality

    80%

    High impact evidenced by foundational mouse genetics/phenome infrastructure and methodological rigor initiatives; however, this assessment is limited by incomplete DOI coverage of the author’s full bibliography in the prompt, so some strengths/drawbacks cannot be fully verified here. Rigor appears strong where resources/checklists are documented, but we cannot judge every individual experimental paper’s design quality from the provided subset. Bias risks: publication/impact metrics reflect adoption and utility, not universal methodological excellence; cross-lab and cross-species generalization remain inherent uncertainties.


    Communication Quality

    70%

    Score is moderate-to-good: the contributions described (resource papers, reporting guidelines, database papers) typically require clear structuring and documentation. But the prompt does not include text excerpts from the author’s own writing, so this is inferred rather than directly evaluated for clarity, pedagogy, or argumentation quality.


    Author Novelty

    70%

    Novelty is credible in the form of community resources and mapping/phenome infrastructure that materially advanced the field. Still, resource-building often involves iterative extension of prior efforts, and this prompt does not enumerate the author’s most pioneering individual experimental hypotheses, limiting certainty.


    Scientific Rigor

    80%

    Strong signals from reproducibility/reporting infrastructure (MIBBI) and from mechanistic immunogenetics and genetics resources. Limitation: we do not have full methods/statistical sections for each experimental claim in the prompt subset, so rigor across the entire publication set cannot be exhaustively audited here.

     Analysis Wizard



    It parses the provided yearly outputs to quantify output/citation trends, then clusters cited works by contribution type using their DOIs and metadata fields to guide targeted follow-up reading.



     Hypothesis Graveyard


    That citation count alone reflects mechanistic truth in a specific biological pathway; unlikely because citations are strongly influenced by adoption/utility and community benchmarking, not only correctness.


    That resource-building automatically guarantees downstream experimental validity; weak assumption because user-defined analysis pipelines and phenotyping procedures can still introduce systematic bias.

     Science Art


    Author Review: Molly A Bogue Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending